Sphingolipid Storage Diseases

These are a group of rare, inherited diseases. They affect how your body breaks down certain fats called sphingolipids. This buildup causes problems, especially in the brain and nerves, leading to various symptoms.

Condition

What people with Sphingolipid Storage Diseases report

Every report comes from a Lived member, sent anonymously.

Have you tried Enzyme Replacement Therapy for Sphingolipid Storage Diseases?

NameHow it went

About Sphingolipid Storage Diseases

What It Is

Sphingolipid storage diseases, also called sphingolipidoses, are a group of rare inherited conditions in which the body cannot properly break down sphingolipids. These are fatty substances that form part of normal cell membranes and of the protective coating (myelin) around nerves. Each disease is caused by a missing or poorly working enzyme inside lysosomes, the compartments cells use to recycle worn-out material. Without that enzyme, the fatty material builds up and gradually damages cells and tissues. The group includes Gaucher disease, Fabry disease, Tay-Sachs and Sandhoff disease, GM1 gangliosidosis, Krabbe disease, metachromatic leukodystrophy (MLD), Niemann-Pick disease types A and B, and Farber disease. They share a mechanism but differ widely in practice. Several begin in infancy and steadily damage the brain and nervous system, causing loss of skills a baby has already learned. Others, such as Gaucher disease type 1 and Fabry disease, mainly affect organs like the spleen, liver, bones, kidneys and heart, and may first appear in childhood or adulthood. Because of this range, the specific type, and often its subtype, matters far more than the group name.

Causes & Risk Factors

Every sphingolipid storage disease is genetic. A change in a single gene leaves the body short of one particular enzyme. Nothing a person or their parents did causes it, and there are no outside triggers that bring the disease on. Most types are autosomal recessive: a child is affected only when both parents pass on a changed copy of the same gene. Parents who each carry one copy are usually healthy and often unaware of it. In each pregnancy, their child has a 25% chance of being affected, a 50% chance of being a carrier like them, and a 25% chance of inheriting neither copy. Fabry disease is the exception. It is X-linked, meaning the gene sits on the X chromosome, so it mainly affects boys and men. Women and girls with one changed copy usually have milder and more variable symptoms, although some become seriously ill. Some types are more common in particular communities, which is why carrier screening is often offered based on ancestry. Tay-Sachs and Gaucher disease occur more often in people of Ashkenazi Jewish descent, and Tay-Sachs is also more common among some French Canadian and Louisiana Cajun families.

How It's Diagnosed

Early symptoms can resemble many other conditions, and several of these diseases look alike, so diagnosis usually involves a specialist in genetic or metabolic disease. The clinician looks for a telling pattern, such as a baby who develops normally and then loses skills, an enlarged liver or spleen, seizures, or, in some types, a cherry-red spot at the back of the eye that an eye examination can reveal. The key tests measure how active the suspected enzyme is, usually in a blood sample, and look for the gene changes that cause the disease. Low enzyme activity points to a specific diagnosis, and the genetic result confirms it and allows relatives to be tested, which is why both tests are usually done. Depending on the type, urine tests or a tissue sample can add information. Some US states screen newborns for certain types, most notably Krabbe disease, so a few babies are identified before any symptoms appear. Carrier testing is available for people with a family history or from communities where a type is more common, and genetic testing can also show whether a pregnancy is affected. A genetic counselor can explain what results mean for a family's future pregnancies.

Treatment Options

Treatment depends entirely on the type. For a few, medicines can control much of the disease in the body. For many others, care focuses on comfort, nutrition and function. Enzyme replacement therapy supplies a manufactured version of the missing enzyme through an intravenous infusion, typically every one to two weeks and continued long term. It is approved for Gaucher disease (for example, imiglucerase, sold as Cerezyme), Fabry disease (for example, agalsidase beta, sold as Fabrazyme), and the non-brain features of Niemann-Pick types A and B, also called acid sphingomyelinase deficiency (olipudase alfa, sold as Xenpozyme). In Gaucher disease it can shrink an enlarged liver and spleen and improve blood counts. Its central limitation is that it does not reach the brain, so it does not treat neurological damage in the types that affect the brain. Infusions can cause allergic reactions, occasionally severe, so infusions are given where reactions can be recognized and treated. Substrate reduction therapy works from the other direction: an oral medicine lowers how much of the fatty material the body makes. Eliglustat (Cerdelga) is an option for some adults with Gaucher disease type 1, after a genetic test shows how their body processes the drug. For Fabry disease, migalastat (Galafold) is a different kind of oral medicine: it helps the person's own, partly working enzyme reach where it is needed, so it works only for adults with certain gene changes. For Krabbe disease and MLD, timing decides what is possible. A stem cell (bone marrow) transplant given before symptoms begin can improve survival and outcomes in infantile Krabbe disease, which is the reason for newborn screening. A gene therapy, atidarsagene autotemcel (Lenmeldy), is approved for certain children with MLD who have no symptoms yet or are at the very start of the early juvenile form; it uses the child's own blood stem cells, modified to make the missing enzyme. Once significant symptoms have developed, these treatments offer much less. For Tay-Sachs, Sandhoff, GM1 gangliosidosis, Niemann-Pick type A and the brain-affecting forms of Gaucher disease, no current treatment stops the brain damage. Supportive care still makes a real difference: seizure medicines, help with feeding and swallowing (sometimes a feeding tube), hydration, and care to keep the airway clear. Research, including gene therapy trials, is active for several types.

What to Expect

The outlook varies more across this group than for almost any other condition name. The infantile forms of Tay-Sachs, Sandhoff, Krabbe, GM1 gangliosidosis, MLD, Niemann-Pick type A and Gaucher type 2 are progressive and usually shorten life to early childhood. Families in this situation typically move from learning the diagnosis to planning care around feeding, seizures, breathing, comfort and time together, with support from a specialist team. Later-onset forms progress more slowly. Juvenile and adult forms of MLD and late-onset Tay-Sachs can unfold over years, with gradual changes in walking, balance, thinking or mood. Gaucher disease type 1 does not usually affect the brain, and treatment becomes part of ordinary life: regular infusions or daily pills, with monitoring of blood counts, organ size and bones. Fabry disease is a lifelong condition in which treatment, along with control of blood pressure and protection of the kidneys, heart and brain (Fabry raises the risk of stroke), aims to slow organ damage. Ongoing care usually involves a team: a metabolic or genetics specialist, neurologists, and other specialists depending on which organs are involved. People with Gaucher disease, and carriers of a Gaucher gene change, have a higher risk of Parkinson's disease. This is a raised risk, not a certainty, and new tremor, stiffness or slowed movement is worth raising with the care team. Because these are inherited conditions, a diagnosis often raises questions for brothers, sisters and other relatives, and testing them can matter, especially when an early treatment exists.

When to Seek Help

Ask for an evaluation if a baby or child stops gaining skills or loses skills they had, has an unusual startle response to noise, or develops a swollen belly from an enlarged liver or spleen. In older children, teens or adults, unexplained burning pain in the hands and feet with reduced sweating, or an enlarged spleen with low blood counts and bone pain, are reasons to ask about these conditions. If a newborn screen flags Krabbe disease or another type, or a brother or sister has just been diagnosed, contact the care team promptly, because for Krabbe disease and MLD the treatments that help work best before symptoms start. Anyone with a family history who is planning a pregnancy can request carrier testing and genetic counseling. People already in treatment should tell their team about new symptoms, changes in walking or swallowing, or milder reactions after infusions. A first seizure, a seizure lasting more than five minutes, or trouble breathing during or after a seizure needs emergency care (call 911). For a child already diagnosed, so does a seizure that does not stop as their seizure plan expects. Trouble breathing, swelling of the face or throat, or fainting during or after an infusion also needs emergency care.

Questions to Ask Your Doctor

  1. 1.Which specific type and subtype is this, and how sure are we based on the enzyme and genetic tests?
  2. 2.Is there a treatment that targets this type, and does it help the brain, the body or both?
  3. 3.How fast is this type likely to progress, and what changes should we plan for over the next year?
  4. 4.Should brothers, sisters or other relatives be tested, and is any of them young enough for early treatment to matter?
  5. 5.Which specialists and support services, including any clinical trials, should be part of our care?

Last reviewed • Oct 2026

Educational content, not medical advice.